Activators in this class would be expected to interact with the receptor in a way that induces a conformational change, leading to the activation of its associated G-protein. This, in turn, triggers a cascade of intracellular events resulting in the functional outcome associated with P2Y5 activation. The chemical compounds would need to be small molecules capable of crossing the extracellular matrix and interacting with the extracellular domain of the P2Y5 receptor without being degraded by extracellular enzymes.
The chemical class known as P2Y5 Activators would encompass a range of compounds with structural affinity for the ligand-binding domain of the receptor. These molecules would need to have the appropriate size, charge, hydrophobicity, and molecular geometry to fit into the binding site of P2Y5. Upon binding, these activators would stabilize the active form of the receptor, promoting G-protein binding, and subsequent signal transduction. The diversity within this chemical class would stem from the variety of functional groups that could interact with the receptor's amino acid residues in the binding pocket, each influencing the receptor dynamics to various extents. Collectively, the molecular characteristics of these activators would be finely tuned to ensure specificity and effectiveness in receptor activation without initiating undesired biological processes.
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Uridine-5′-triphosphate, Trisodium Salt | 19817-92-6 | sc-301964 sc-301964A | 50 mg 1 g | $86.00 $118.00 | 2 | |
UTP, like ATP, is a naturally occurring nucleotide that can act on P2 receptors. Synthetic UTP might serve as an agonist for P2Y receptors, potentially interacting with P2Y5 or modulating its signaling pathway thus promoting its activation. | ||||||
Clopidogrel | 113665-84-2 | sc-507403 | 1 g | $120.00 | 1 | |
Clopidogrel is an inhibitor of ADP-mediated platelet aggregation by irreversibly modifying the P2Y12 receptor. Its modulation of purinergic signaling could indirectly influence P2Y5 receptor activity. |